Hyperkalemic PP Medications
The primary goals of treating hyperPP are to alleviate acute attack symptoms, prevent and manage immediate complications, and reduce the risk of both future attacks and late complications. Treatment involves a multi-layered approach, combining medications, dietary adjustments, and trigger management. These strategies have proven highly beneficial for most patients. However, individual responses to treatment vary, making it essential to work closely with your medical provider to develop a personalized plan that best suits your needs.
Carbonic Anhydrase Inhibitors
Acetazolamide is a commonly used treatment to reduce episodes of muscle weakness / paralysis in hypokalemic periodic paralysis patients. Acetazolamides effectiveness can vary from patient to patient. To learn more, please click on the button below:
Dichlorphenamide is an FDA approved carbonic anhydrase inhibitor indicated for the treatment of primary hyperkalemic periodic paralysis, primary hypokalemic periodic paralysis, and related variants. Dichlorphenamide is available in both brand-name and generic forms.
To learn more about a prescription medication for the treatment of Primary Periodic Paralysis (PPP), patient support, and available tools and resources from Xeris Pharmaceuticals®, click below.
Other Medications
Albuterol is an inhaled medication used to treat shortness of breath and wheezing in patients with asthma and COPD. Albuterol lowers potassium and is used in some patients with hyper variants for acute attacks.